Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/221349
Title: Real-world experience of Teduglutide use in adults with short bowel syndrome: A seven-year international multicenter survey
Author: Joly, Francisca
Jezerski, Denise
Pape, Ulrich-Frank
Crivelli, Adriana
Huetterer, Elisabeth
Bergoin, Charlotte
Sasdelli, Anna Simona
Aimasso, Umberto
Schneider, Stéphane M.
Poullenot, Florian
Seguy, David
Chapman, Brooke
Sobocki, Jacek
Regano, Nunzia
Lamprecht, Georg
Layec, Sabrina
Santarpia, Lidia
Kozjek, Nada Rotovnik
Gallitelli, Livia
López Urdiales, Rafael
Fehr, Rebecca
Itzhaki, Moran Hellerman
Maíz Jiménez, María
Carey, Sharon
Taus, Marina
Francini Pesenti, Francesco
Rasmussen, Henrik H.
Vanuytsel, Tim
Cuerda Compes, Cristina
Thibault, Ronan
Chen, Mona
Osland, Emma
Krznaric, Zeljko
Martins da Rocha, Mariana Hollanda
Martinuzzi, Andrés L. N.
Bezmarevic, Mihailo
Bueno Diez, Marta
Livovsky, Dan M.
Serrano Aguayo, Pilar
Orlandoni, Paolo
Burgos Peláez, Rosa
Campos Martín, Cristina
Ellegard, Lars
Lezo, Antonella
Ramos Boluda, Esther
Gandullia, Paolo
Bluethner, Elizabeth
Zarpellon, Martina
Lal, Simon
Pironi, Loris
Keywords: Malalties de l'aparell digestiu
Terapèutica
Digestive system diseases
Therapeutics
Issue Date: 17-Feb-2025
Publisher: Elsevier BV
Abstract: Background and aim: Teduglutide is a glucagon-like peptide-2 analogue used to promote intestinal rehabilitation and decrease the dependence from intravenous supplementation (IVS) in patients with short bowel syndrome and intestinal failure (SBS-IF). The aim of this study was to gain a better understanding of international real-world Teduglutide use since its launch. Methods: Data from an international multicenter database for chronic IF were analysed. All the adult patients with SBS-IF included by centers that treated at least one patient with Teduglutide during the study period (2015-2022) were investigated. The baseline characteristics and the outcome of patients treated with Teduglutide (n.269) were compared to those of patients not receiving the drug (Controls, n.3081). The center experience was categorized based on the number of patients treated with Teduglutide: <10 or >= 10. Results: Teduglutide cohort exhibited higher male prevalence, younger age, longer duration of HPN, higher percentage of SBS with jejunocolonic anastomosis, lower IVS volume, improved oral intake, and higher percentage of patients weaned from IVS. Controls showed higher percentages of patients deceased or lost to follow up. Centers with >= 10 patients treated with Teduglutide showed higher weaning rates and lower mortality rates. Conclusions: This is the largest analysis of Teduglutide's real-world setting in SBS-IF. Clinicians preferentially selected for treatment patients with better prognostic indicators. Outcomes were significantly better in centers with higher Teduglutide treatment volumes, emphasizing the need for specialized referral centers to optimize care for SBS-IF patients. (c) 2025 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
Note: Reproducció del document publicat a: https://doi.org/10.1016/j.clnu.2025.01.026
It is part of: Clinical Nutrition, 2025, vol. 47, p. 54-67
URI: https://hdl.handle.net/2445/221349
Related resource: https://doi.org/10.1016/j.clnu.2025.01.026
ISSN: 0261-5614
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
1-s2.0-S0261561425000275-main.pdf480.32 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons